SOL-1 phase 3 Readout: Key Efficacy and Safety Outcomes in Neovascular AMD

Dr. Khanani reviews 52-week safety outcomes, noting Axpaxli was generally well tolerated with no cases of endophthalmitis or retinal vasculitis.

In this opening segment, Dr. Arshad Khanani highlights the SOL-1 phase 3 trial evaluating Axpaxli (OTX-TKI) in treatment-naïve neovascular AMD.